APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

Selected research

Industry Research

GLP-1 Drug Industry Research Report 2026

21 December 2025128 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Read the full market overview

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

The global GLP-1 Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for GLP-1 Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for GLP-1 Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for GLP-1 Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of GLP-1 Drug include Novo Nordisk, Eli Lilly, Sanofi, Teva, Jiangsu Hansoh Pharmaceutical, Huadong Medicine, Benemae Pharmaceutical, Tonghua Dongbao Pharma and Chia Tai-Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global GLP-1 Drug market in terms of revenue (US$ million) and, where applicable, sales volume (Sales (k PMT)), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Sales (k PMT)) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

GLP-1 Drug Market by Company

Novo Nordisk

Eli Lilly

Sanofi

Teva

Jiangsu Hansoh Pharmaceutical

Huadong Medicine

Benemae Pharmaceutical

Tonghua Dongbao Pharma

Chia Tai-Tianqing Pharmaceutical

AstraZeneca

GLP-1 Drug Segment by Type

Short-acting

Long-acting

GLP-1 Drug Segment by Indications

T2D

CV risk

Obesity

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of GLP-1 Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of GLP-1 Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by indications, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Indications (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global GLP-1 Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global GLP-1 Drug Sales (Sales (k PMT)) of Manufacturers (2021-2026) Table 7. Global GLP-1 Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global GLP-1 Drug Revenue of Manufacturers (2021-2026) Table 9. Global GLP-1 Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market GLP-1 Drug Average Price (Net Price (USD/PMT)) of Manufacturers (2021-2026) Table 11. Global GLP-1 Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of GLP-1 Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of GLP-1 Drug, Product Type & Application Table 14. Global GLP-1 Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global GLP-1 Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Novo Nordisk Company Information Table 19. Novo Nordisk Business Overview Table 20. Novo Nordisk GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 21. Novo Nordisk GLP-1 Drug Product Portfolio Table 22. Novo Nordisk Recent Developments Table 23. Eli Lilly Company Information Table 24. Eli Lilly Business Overview Table 25. Eli Lilly GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 26. Eli Lilly GLP-1 Drug Product Portfolio Table 27. Eli Lilly Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 31. Sanofi GLP-1 Drug Product Portfolio Table 32. Sanofi Recent Developments Table 33. Teva Company Information Table 34. Teva Business Overview Table 35. Teva GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 36. Teva GLP-1 Drug Product Portfolio Table 37. Teva Recent Developments Table 38. Jiangsu Hansoh Pharmaceutical Company Information Table 39. Jiangsu Hansoh Pharmaceutical Business Overview Table 40. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 41. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio Table 42. Jiangsu Hansoh Pharmaceutical Recent Developments Table 43. Huadong Medicine Company Information Table 44. Huadong Medicine Business Overview Table 45. Huadong Medicine GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 46. Huadong Medicine GLP-1 Drug Product Portfolio Table 47. Huadong Medicine Recent Developments Table 48. Benemae Pharmaceutical Company Information Table 49. Benemae Pharmaceutical Business Overview Table 50. Benemae Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 51. Benemae Pharmaceutical GLP-1 Drug Product Portfolio Table 52. Benemae Pharmaceutical Recent Developments Table 53. Tonghua Dongbao Pharma Company Information Table 54. Tonghua Dongbao Pharma Business Overview Table 55. Tonghua Dongbao Pharma GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 56. Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio Table 57. Tonghua Dongbao Pharma Recent Developments Table 58. Chia Tai-Tianqing Pharmaceutical Company Information Table 59. Chia Tai-Tianqing Pharmaceutical Business Overview Table 60. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 61. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio Table 62. Chia Tai-Tianqing Pharmaceutical Recent Developments Table 63. AstraZeneca Company Information Table 64. AstraZeneca Business Overview Table 65. AstraZeneca GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 66. AstraZeneca GLP-1 Drug Product Portfolio Table 67. AstraZeneca Recent Developments Table 68. Global GLP-1 Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global GLP-1 Drug Sales by Region (2021-2026) & (Sales (k PMT)) Table 70. Global GLP-1 Drug Sales Market Share by Region (2021-2026) Table 71. Global GLP-1 Drug Sales by Region (2027-2032) & (Sales (k PMT)) Table 72. Global GLP-1 Drug Sales Market Share by Region (2027-2032) Table 73. Global GLP-1 Drug Revenue by Region (2021-2026) & (US$ Million) Table 74. Global GLP-1 Drug Revenue Market Share by Region (2021-2026) Table 75. Global GLP-1 Drug Revenue by Region (2027-2032) & (US$ Million) Table 76. Global GLP-1 Drug Revenue Market Share by Region (2027-2032) Table 77. North America GLP-1 Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 79. North America GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 80. North America GLP-1 Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. North America GLP-1 Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe GLP-1 Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 84. Europe GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 85. Europe GLP-1 Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe GLP-1 Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific GLP-1 Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 89. Asia Pacific GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 90. Asia Pacific GLP-1 Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific GLP-1 Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. South America GLP-1 Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 94. South America GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 95. South America GLP-1 Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. South America GLP-1 Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa GLP-1 Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 99. Middle East and Africa GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 100. Middle East and Africa GLP-1 Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa GLP-1 Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Global GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 103. Global GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 104. Global GLP-1 Drug Sales Market Share by Type (2021-2026) Table 105. Global GLP-1 Drug Sales Market Share by Type (2027-2032) Table 106. Global GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. Global GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. Global GLP-1 Drug Revenue Market Share by Type (2021-2026) Table 109. Global GLP-1 Drug Revenue Market Share by Type (2027-2032) Table 110. Global GLP-1 Drug Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 111. Global GLP-1 Drug Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 112. Global GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 113. Global GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 114. Global GLP-1 Drug Sales Market Share by Indications (2021-2026) Table 115. Global GLP-1 Drug Sales Market Share by Indications (2027-2032) Table 116. Global GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 117. Global GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 118. Global GLP-1 Drug Revenue Market Share by Indications (2021-2026) Table 119. Global GLP-1 Drug Revenue Market Share by Indications (2027-2032) Table 120. Global GLP-1 Drug Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 121. Global GLP-1 Drug Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. GLP-1 Drug Distributors List Table 125. GLP-1 Drug Customers List Table 126. GLP-1 Drug Industry Trends Table 127. GLP-1 Drug Industry Drivers Table 128. GLP-1 Drug Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. GLP-1 Drug Product Image Figure 5. Global GLP-1 Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global GLP-1 Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global GLP-1 Drug Sales (2021-2032) & (Sales (k PMT)) Figure 8. Global GLP-1 Drug Average Price (Net Price (USD/PMT)) & (2021-2032) Figure 9. Short-acting Product Image Figure 10. Long-acting Product Image Figure 11. T2D Product Image Figure 12. CV risk Product Image Figure 13. Obesity Product Image Figure 14. Global GLP-1 Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of GLP-1 Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 GLP-1 Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global GLP-1 Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global GLP-1 Drug Sales by Region in 2025 Figure 20. Global GLP-1 Drug Revenue by Region in 2025 Figure 21. North America GLP-1 Drug Market Size by Country in 2025 Figure 22. North America GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 23. North America GLP-1 Drug Revenue Market Share by Country (2021-2032) Figure 24. United States GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe GLP-1 Drug Market Size by Country in 2025 Figure 28. Europe GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 29. Europe GLP-1 Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific GLP-1 Drug Market Size by Country in 2025 Figure 41. Asia Pacific GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific GLP-1 Drug Revenue Market Share by Country (2021-2032) Figure 43. China GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America GLP-1 Drug Market Size by Country in 2025 Figure 52. South America GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 53. South America GLP-1 Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa GLP-1 Drug Market Size by Country in 2025 Figure 58. Middle East and Africa GLP-1 Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa GLP-1 Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries GLP-1 Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global GLP-1 Drug Sales Market Share by Type (2021-2032) Figure 66. Global GLP-1 Drug Revenue Market Share by Type (2021-2032) Figure 67. Global GLP-1 Drug Price (Net Price (USD/PMT)) by Type (2021-2032) Figure 68. Global GLP-1 Drug Sales Market Share by Indications (2021-2032) Figure 69. Global GLP-1 Drug Revenue Market Share by Indications (2021-2032) Figure 70. Global GLP-1 Drug Price (Net Price (USD/PMT)) by Indications (2021-2032) Figure 71. GLP-1 Drug Value Chain Figure 72. GLP-1 Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. GLP-1 Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Short-acting
  • Long-acting
Applications
  • T2D
  • CV risk
  • Obesity
Companies covered
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Teva
  • Jiangsu Hansoh Pharmaceutical
  • Huadong Medicine
  • Benemae Pharmaceutical
  • Tonghua Dongbao Pharma
  • Chia Tai-Tianqing Pharmaceutical
  • AstraZeneca

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global GLP-1 Drug Market Size (2021-2032)
  4. 2.2.2 Global GLP-1 Drug Sales (2021-2032)
  5. 2.2.3 Global GLP-1 Drug Market Average Price (2021-2032)
  6. 2.3 GLP-1 Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Short-acting
  9. 2.3.3 Long-acting
  10. 2.4 GLP-1 Drug by Indications
  11. 2.4.1 Market Value Comparison by Indications (2021 VS 2025 VS 2032)
  12. 2.4.2 T2D
  13. 2.4.3 CV risk
  14. 2.4.4 Obesity
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global GLP-1 Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global GLP-1 Drug Sales (Sales (k PMT)) of Manufacturers (2021-2026)
  3. 3.3 Global GLP-1 Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global GLP-1 Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global GLP-1 Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of GLP-1 Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of GLP-1 Drug, Product Type & Application
  8. 3.8 Global Manufacturers of GLP-1 Drug, Established Date
  9. 3.9 Global GLP-1 Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Novo Nordisk
  2. 4.1.1 Novo Nordisk Company Information
  3. 4.1.2 Novo Nordisk Business Overview
  4. 4.1.3 Novo Nordisk GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Novo Nordisk GLP-1 Drug Product Portfolio
  6. 4.1.5 Novo Nordisk Recent Developments
  7. 4.2 Eli Lilly
  8. 4.2.1 Eli Lilly Company Information
  9. 4.2.2 Eli Lilly Business Overview
  10. 4.2.3 Eli Lilly GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Eli Lilly GLP-1 Drug Product Portfolio
  12. 4.2.5 Eli Lilly Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi GLP-1 Drug Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Teva
  20. 4.4.1 Teva Company Information
  21. 4.4.2 Teva Business Overview
  22. 4.4.3 Teva GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Teva GLP-1 Drug Product Portfolio
  24. 4.4.5 Teva Recent Developments
  25. 4.5 Jiangsu Hansoh Pharmaceutical
  26. 4.5.1 Jiangsu Hansoh Pharmaceutical Company Information
  27. 4.5.2 Jiangsu Hansoh Pharmaceutical Business Overview
  28. 4.5.3 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio
  30. 4.5.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  31. 4.6 Huadong Medicine
  32. 4.6.1 Huadong Medicine Company Information
  33. 4.6.2 Huadong Medicine Business Overview
  34. 4.6.3 Huadong Medicine GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Huadong Medicine GLP-1 Drug Product Portfolio
  36. 4.6.5 Huadong Medicine Recent Developments
  37. 4.7 Benemae Pharmaceutical
  38. 4.7.1 Benemae Pharmaceutical Company Information
  39. 4.7.2 Benemae Pharmaceutical Business Overview
  40. 4.7.3 Benemae Pharmaceutical GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Benemae Pharmaceutical GLP-1 Drug Product Portfolio
  42. 4.7.5 Benemae Pharmaceutical Recent Developments
  43. 4.8 Tonghua Dongbao Pharma
  44. 4.8.1 Tonghua Dongbao Pharma Company Information
  45. 4.8.2 Tonghua Dongbao Pharma Business Overview
  46. 4.8.3 Tonghua Dongbao Pharma GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio
  48. 4.8.5 Tonghua Dongbao Pharma Recent Developments
  49. 4.9 Chia Tai-Tianqing Pharmaceutical
  50. 4.9.1 Chia Tai-Tianqing Pharmaceutical Company Information
  51. 4.9.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  52. 4.9.3 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio
  54. 4.9.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  55. 4.10 AstraZeneca
  56. 4.10.1 AstraZeneca Company Information
  57. 4.10.2 AstraZeneca Business Overview
  58. 4.10.3 AstraZeneca GLP-1 Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 AstraZeneca GLP-1 Drug Product Portfolio
  60. 4.10.5 AstraZeneca Recent Developments
5 Global GLP-1 Drug Market Scenario by Region
  1. 5.1 Global GLP-1 Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global GLP-1 Drug Sales by Region: 2021-2032
  3. 5.2.1 Global GLP-1 Drug Sales by Region: 2021-2026
  4. 5.2.2 Global GLP-1 Drug Sales by Region: 2027-2032
  5. 5.3 Global GLP-1 Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global GLP-1 Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global GLP-1 Drug Revenue by Region: 2027-2032
  8. 5.4 North America GLP-1 Drug Market Facts & Figures by Country
  9. 5.4.1 North America GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America GLP-1 Drug Sales by Country (2021-2032)
  11. 5.4.3 North America GLP-1 Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe GLP-1 Drug Market Facts & Figures by Country
  16. 5.5.1 Europe GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe GLP-1 Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe GLP-1 Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific GLP-1 Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific GLP-1 Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific GLP-1 Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America GLP-1 Drug Market Facts & Figures by Country
  41. 5.7.1 South America GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America GLP-1 Drug Sales by Country (2021-2032)
  43. 5.7.3 South America GLP-1 Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa GLP-1 Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa GLP-1 Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa GLP-1 Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa GLP-1 Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global GLP-1 Drug Sales by Type (2021-2032)
  2. 6.1.1 Global GLP-1 Drug Sales by Type (2021-2032) & (Sales (k PMT))
  3. 6.1.2 Global GLP-1 Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global GLP-1 Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global GLP-1 Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global GLP-1 Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global GLP-1 Drug Price by Type (2021-2032)
7 Segment by Indications
  1. 7.1 Global GLP-1 Drug Sales by Indications (2021-2032)
  2. 7.1.1 Global GLP-1 Drug Sales by Indications (2021-2032) & (Sales (k PMT))
  3. 7.1.2 Global GLP-1 Drug Sales Market Share by Indications (2021-2032)
  4. 7.2 Global GLP-1 Drug Revenue by Indications (2021-2032)
  5. 7.2.1 Global GLP-1 Drug Sales by Indications (2021-2032) & (US$ Million)
  6. 7.2.2 Global GLP-1 Drug Revenue Market Share by Indications (2021-2032)
  7. 7.3 Global GLP-1 Drug Price by Indications (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 GLP-1 Drug Value Chain Analysis
  2. 8.1.1 GLP-1 Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 GLP-1 Drug Production Mode & Process
  5. 8.2 GLP-1 Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 GLP-1 Drug Distributors
  8. 8.2.3 GLP-1 Drug Customers
9 Global GLP-1 Drug Analyzing Market Dynamics
  1. 9.1 GLP-1 Drug Industry Trends
  2. 9.2 GLP-1 Drug Industry Drivers
  3. 9.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 9.4 GLP-1 Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst